Case report: immune-mediated cerebellar ataxia secondary to anti-PD-L1 treatment for lung cancer.
Int J Neurosci
; 129(12): 1223-1225, 2019 Dec.
Article
em En
| MEDLINE
| ID: mdl-31414604
ABSTRACT
Case presentation A 66-year-old gentleman with metastatic non-small-cell lung cancer developed a wide-based gait following treatment on a clinical trial with cytotoxic chemotherapy and an anti-PD-L1 drug. He had no other significant past medical history of note. Brain imaging, blood tests and lumbar puncture did not reveal a structural, biochemical, paraneoplastic or infective cause. The main differential diagnoses were immune-mediated toxicity or a paraneoplastic syndrome. He was started on prednisolone on the suspicion that his symptoms represented an immune-mediated toxicity. His condition improved following this and his immunotherapy treatment was discontinued. Upon steroid withdrawal, his symptoms recurred and responded to further prednisolone. Conclusions:
Immune-mediated toxicities can affect any part of the nervous system and should form part of the differential diagnosis for new neurological symptoms in a patient receiving immunotherapy. Corticosteroids should be the first-line treatment of immune-mediated toxicities. Immunotherapy should be permanently discontinued following severe toxicities.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Ataxia Cerebelar
/
Carcinoma Pulmonar de Células não Pequenas
/
Anticorpos Monoclonais Humanizados
/
Imunoterapia
/
Antineoplásicos
Tipo de estudo:
Diagnostic_studies
Limite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
Int J Neurosci
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Reino Unido